| Leni Soloaga, MSCCCSLP | |
|
890 N Cole Rd, Ste A, Boise, ID 83704-8638 | |
| (208) 323-8888 | |
| (208) 323-8889 |
| Full Name | Leni Soloaga |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 890 N Cole Rd, Boise, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528191640 | NPI | - | NPPES |
| 000010157677 | Other | ID | REGENCE BLUE SHIELD |
| 12003265 | Other | ASHA | |
| SLP05 | Other | ID | BLUE CROSS PROVIDER # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SLP-1546 (Idaho) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Leni Soloaga, MSCCCSLP 12472 W Norristown St, Boise, ID 83709-8123 Ph: (208) 420-0109 | Leni Soloaga, MSCCCSLP 890 N Cole Rd, Ste A, Boise, ID 83704-8638 Ph: (208) 323-8888 |
News Archive
Critical Path Institute announced today that the Biomarker Qualification Program at the Center for Drug Evaluation and Research in the U.S. Food and Drug Administration issued a positive response to the Letter of Intent developed by C-Path's Predictive Safety Testing Consortium and Duchenne Regulatory Science Consortium, for a panel of four safety biomarkers of acute drug-induced skeletal muscle injury.
If you were fortunate enough to witness the recent total solar eclipse in all its glory, you might have noticed something surprising.
The American Society of Human Genetics (ASHG) has named R. Rodney Howell, MD, Professor in the Department of Pediatrics, Chairman Emeritus of Pediatrics, and Member of the Hussman Institute for Human Genomics, at the University of Miami Leonard M. Miller School of Medicine, as the first recipient of its new, annual Advocacy Award.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.
› Verified 9 days ago
Jennifer Dahms, MS/CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2995 N Cole Rd, Suite 130, Boise, ID 83704 Phone: 208-559-2348 Fax: 888-559-4660 | |
Lauren Rose Addison, M.S. SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 8620 W Emerald St Ste 100, Boise, ID 83704 Phone: 208-898-1368 | |
Kelli Shaw, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3115 N Sycamore Dr, Boise, ID 83703 Phone: 208-401-6401 | |
Christy Baltazor, M.S., CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2127 W Overland Rd, Boise, ID 83705 Phone: 208-321-4898 | |
Megan Patrick, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2127 W Overland Rd, Boise, ID 83705 Phone: 208-321-4898 | |
Emily Chapman, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8860 W Evening Star Ln, Boise, ID 83709 Phone: 814-873-9144 | |
Kimberly Degraw, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 901 N Curtis Rd Ste 204, Boise, ID 83706 Phone: 208-367-8282 |